These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29913473)

  • 21. Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study.
    Lagacé-Wiens PR; Simner PJ; Forward KR; Tailor F; Adam HJ; Decorby M; Karlowsky J; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):314-9. PubMed ID: 21353959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
    Harris PN; Peleg AY; Iredell J; Ingram PR; Miyakis S; Stewardson AJ; Rogers BA; McBryde ES; Roberts JA; Lipman J; Athan E; Paul SK; Baker P; Harris-Brown T; Paterson DL
    Trials; 2015 Jan; 16():24. PubMed ID: 25623485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of complicated urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Hawboldt J; Brooks A
    Postgrad Med; 2010 Nov; 122(6):7-15. PubMed ID: 21084776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region.
    Hsueh PR; Hoban DJ; Carmeli Y; Chen SY; Desikan S; Alejandria M; Ko WC; Binh TQ
    J Infect; 2011 Aug; 63(2):114-23. PubMed ID: 21669223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftazidime/Avibactam (Avycaz) -- a new intraveneous antibiotic.
    Med Lett Drugs Ther; 2015 May; 57(1469):79-80. PubMed ID: 25989198
    [No Abstract]   [Full Text] [Related]  

  • 30. Postoperative bacteriuria, pyuria and urinary tract infection in patients with an orthotopic sigmoid colon neobladder replacement.
    Shigemura K; Tanaka K; Arakawa S; Miyake H; Fujisawa M
    J Antibiot (Tokyo); 2014 Feb; 67(2):143-5. PubMed ID: 24169796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    J Chemother; 2005 Oct; 17(5):459-69. PubMed ID: 16323433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newer carbapenems for urinary tract infections.
    Matsumoto T; Muratani T
    Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S35-8. PubMed ID: 15364304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
    Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K
    Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carumonam versus ceftazidime: in vitro activity, pharmacokinetics in elderly patients, safety and therapeutic efficacy in the treatment of complicated urinary tract infections.
    Naber K; Kees F; Denk K; Bauernfeind A; Grobecker H
    Chemioterapia; 1987 Jun; 6(2 Suppl):517-8. PubMed ID: 3334613
    [No Abstract]   [Full Text] [Related]  

  • 35. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).
    Flamm RK; Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):233-8. PubMed ID: 25128477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.
    Vazquez JA; González Patzán LD; Stricklin D; Duttaroy DD; Kreidly Z; Lipka J; Sable C
    Curr Med Res Opin; 2012 Dec; 28(12):1921-31. PubMed ID: 23145859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.
    Nomura S; Nagayama A
    J Chemother; 2002 Apr; 14(2):155-60. PubMed ID: 12017370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
    Zhanel GG; Mayer M; Laing N; Adam HJ
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2228-30. PubMed ID: 16723591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
    Huband MD; Castanheira M; Flamm RK; Farrell DJ; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2537-41. PubMed ID: 26810650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.